Apr 04, 2023 / 01:00PM GMT
Debjit Chattopadhyay - Guggenheim Partners - Analyst
Good morning and welcome to day two of Guggenheim's Genomic Medicine Rare Disease conference. This is our fifth edition. My name is Debjit, and I'm one of the therapeutic analysts at Guggenheim. My privilege to host Dipal Doshi -- Doshi is CEO of Entrada -- and Natarajan Sethuraman, Chief Scientific Officer. Thank you and good morning and welcome to you both.
Dipal Doshi - Entrada Therapeutics, Inc. - President & CEO
Thanks, Debjith. Great to be here, and thanks for giving us the opportunity to present the Entrada story.
Questions and Answers:
Debjit Chattopadhyay - Guggenheim Partners - AnalystGreat. So, maybe we could just get started on your EEV platform and how this approach might be superior in partitioning to the target relative to the other delivery approaches in neuromuscular diseases?
Dipal Doshi - Entrada Therapeutics, Inc. - President & CEO
Sure. Yeah. I can start and of course, Natarajan and I